BCL2 and acute myeloid leukemia: In sharp contrast, the nanomolar BCL2-specific inhibitor venetoclax (ABT-199, GDC-0199) proved effective in most hematologic malignancies and was soon approved for the therapy of patients with CLL and AML (Table 3) [65,71,72,73,74,75].